

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



奧園健康生活集團有限公司
AOYUAN HEALTHY LIFE GROUP COMPANY LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3662)

**APPOINTMENTS OF CHAIRMAN OF THE BOARD AND
NON-EXECUTIVE DIRECTORS
AND
CHANGE OF COMPOSITION OF NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (the “**Directors**”) of Aoyuan Healthy Life Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that with effect from 20 October 2023:

- (a) Mr. Li Huiqiang (李惠強) (“**Mr. Li**”) has been appointed as the chairman of the Board, a non-executive Director, and the chairman of the nomination committee of the Company (the “**Nomination Committee**”), and is responsible for providing opinion on the overall management and strategic planning to the Board;
- (b) Ms. Jiang Nan (江楠) (“**Ms. Jiang**”) has been appointed as a non-executive Director and is responsible for providing opinion to the Board in connection with the property management operation and the recent development on the property management services; and
- (c) Mr. Cheng Siu Fai (“**Mr. Cheng**”), an executive Director, has resigned as the chairman of the Nomination Committee.

(1) APPOINTMENT OF MR. LI

The biographical details of Mr. Li are as follows:

Mr. Li, aged 51, obtained an Executive Master of Business Administration at Jinan University (暨南大學) in 2016. As of the date of this announcement, Mr. Li holds interests in NanYue StarBridge LPF (南粵星橋有限合夥基金) (“**NanYue StarBridge LPF**”), which is interested in the entire issued share capital of Best Discovery International Limited, which in turn holds 217,148,750 shares of the Company, representing approximately 29.9% of the issued shares of the Company. Mr. Li is also a director and is holding the entire issued share capital of (a) Zhong Xin Global Limited (眾鑫國際有限公司), being the limited partner of NanYue StarBridge LPF, and (b) StarBridge Hong Kong Limited (香港星橋有限公司), being the general partner of NanYue StarBridge LPF. Mr. Li is an engineer with over 20 years of experience. Mr. Li served as a managing director of Chenhui Construction Engineering Group Co., Ltd.* (晨輝建築工程(集團)有限公司), a company established in the People’s Republic of China (the “**PRC**”) and principally engaged in construction, garden engineering, property management, decoration, commerce, investment and other fields, from 2015 to 2020 and a general manager of Guangzhou Panyu Qiaoxing Construction and Installation Engineering Co., Ltd.* (廣州番禺橋興建設安裝工程有限公司), a company established in the PRC and principally engaged in providing contracting services and engineering construction, from 2000 to 2014.

Mr. Li has entered into a letter of appointment with the Company for an initial term of three years commencing from 20 October 2023 which can be terminated by either party giving not less than three months’ prior written notice. Mr. Li is eligible for re-election at the first annual general meeting of the Company after his appointment and be subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company.

Mr. Li is entitled to receive a salary of RMB150,000 per annum, which is commensurate with his duties and responsibilities as the chairman of the Board, a non-executive Director and the chairman of the Nomination Committee and the prevailing market situation and discretionary bonuses pegged to his performance.

Save as disclosed above, Mr. Li is not interested in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

(2) APPOINTMENT OF MS. JIANG

The biographical details of Ms. Jiang are as follows:

Ms. Jiang, aged 42, graduated from the Department of Literature and Arts at Beijing Broadcasting Institute (北京廣播學院) (currently Communication University of China (中國傳媒大學)) in 2004 with a Bachelor of Radio and Television Production and Directing. She has over 19 years of experience in corporate management. Since March 2016, Ms. Jiang served as the general manager of Perrier Health Management Limited, a company established in Hong Kong and principally engaged in investment in the general health industry. From September 2004 to February 2016, Ms. Jiang served as the general manager of Guangzhou Panyu Jinsui Auto Parts Plant* (廣州市番禺金穗汽車配件廠), a company established in the PRC and principally engaged in metal processing and mechanical manufacturing.

Ms. Jiang has entered into a letter of appointment with the Company for an initial term of three years commencing from 20 October 2023 which can be terminated by either party giving not less than three months' prior written notice. Ms. Jiang is eligible for re-election at the first annual general meeting of the Company after her appointment and be subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company.

Ms. Jiang is entitled to receive a salary of RMB150,000 per annum, which is commensurate with her duties and responsibilities as a non-executive Director and the prevailing market situation and discretionary bonuses pegged to her performance.

As at the date of this announcement, Ms. Jiang is not interested in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, to the best knowledge of the Directors, as at the date of this announcement, neither Mr. Li nor Ms. Jiang:

- (a) has held any other major appointment and qualification or directorship in other listed companies in Hong Kong or overseas in the three years preceding the date of this announcement;
- (b) holds any other position in the Company or other members of the Group; and

- (c) has any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”)) of the Company.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules nor any other matters in relation to the appointments of Mr. Li and Ms. Jiang that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to express its warmest welcome to Mr. Li and Ms. Jiang for joining the Board.

(3) CHANGE OF COMPOSITION OF NOMINATION COMMITTEE

With effect from 20 October 2023, Mr. Cheng has resigned as the chairman of the Nomination Committee. Mr. Cheng has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation as the chairman of the Nomination Committee that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

Following the above change and the appointment of Mr. Li, the Nomination Committee comprises Mr. Li as the chairman, Mr. Hung Ka Hai Clement, Dr. Li Zijun and Mr. Wang Shao, being the independent non-executive Directors, as the members.

By the order of the Board
Aoyuan Healthy Life Group Company Limited
Cheng Siu Fai
Executive Director

Hong Kong, 20 October 2023

- * *All of the English titles or names of the entities in the PRC, as well as certain items contained in this announcement have been included for identification purpose only. If there is any inconsistency, the Chinese titles or names shall prevail.*

As at the date of this announcement, the executive Director is Mr. Cheng Siu Fai; the non-executive Directors are Mr. Li Huiqiang, Mr. Ruan Yongxi, Mr. Zhu Yunfan and Ms. Jiang Nan; and the independent non-executive Directors are Mr. Hung Ka Hai Clement, Dr. Li Zijun and Mr. Wang Shao.